Biotech company BioMarin Pharmacuetical's (BMRN) shares are moving sharply higher on heavy volume in Friday's session. This on talk that French pharmaceutical giant, Sanofi (SNY) might be looking to buy the orphan drugmaker. Financial blog Betaville reports that Sanofi has shifted its focus to BioMarin, frustrated after its advances for Medivation have been rejected. But TheStreet's Alicia McElhaney says the talk may be nothing more than just that. Jeanne Yurman reports.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.